Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2021-12-27 Regulatory Filings
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Infant Bacterial Therapeutics tillkännager idag att nya patent har godkänts i Brasilien samt i Hong Kong
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Pressmeddelande" (Press Release) dated December 27, 2021. It announces specific corporate news: the granting of new patents in Brazil and Hong Kong for their drug candidate IBP-9414. The text concludes with contact information and a statement about public disclosure under EU market abuse regulation. This format—a brief, timely announcement of a specific corporate event (patent grant)—does not fit the definitions for comprehensive reports (10-K, IR, AR), financial results (ER, MRQ), or shareholder materials (AGM-R, DEF 14A). Since it is a specific, material corporate announcement that doesn't fit the other specialized categories (like DIRS, M&A, DIV), it falls best under the general regulatory announcement category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory disclosures.
2021-12-27 Swedish
Infant Bacterial Therapeutics today announces new patent protection approvals in Brazil and in Hong Kong
Regulatory Filings Classification · 100% confidence The document is explicitly titled as a "Press Release" dated December 27, 2021. The content focuses on the announcement of new patent protection approvals in Brazil and Hong Kong for their drug candidate IBP-9414. This type of announcement, concerning intellectual property (IP) and specific regulatory/legal milestones (patents), does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). While it relates to IP, it is not a formal Legal Proceedings Report (LTR) detailing lawsuits, nor is it a general Investor Presentation (IP). Since it is a specific, non-standard regulatory/corporate update that doesn't fit the other defined categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements.
2021-12-27 English
Infant Bacterial Therapeutics CFO leaves the company
Board/Management Information Classification · 98% confidence The document is a short press release dated December 10, 2021, announcing that the CFO, Marie Louise Alamaa, has left the company and the Controller, Michael Owens, has assumed the role. This directly relates to a change in senior management. Based on the definitions, this fits the 'Board/Management Information' category (MANG). The document length is short (2173 chars), but it is the primary announcement itself, not an announcement *of* another report, so RPA/RNS is not the primary classification.
2021-12-10 English
Infant Bacterial Therapeutics CFO lämnar bolaget
Board/Management Information Classification · 98% confidence The document is a short press release dated December 10, 2021, announcing that the Chief Financial Officer (CFO) of Infant Bacterial Therapeutics AB has left the company and a replacement has been appointed. This constitutes an announcement of a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (2159 chars) and it is a direct announcement, not a report itself. Therefore, MANG is the most appropriate classification.
2021-12-10 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding for an entity (Quilter Plc) concerning shares in Infant Bacterial Therapeutics AB. Specifically, it shows the 'Before the transaction' holdings (920,499 shares) and the 'After the transaction' holdings (0 shares) due to a 'Sell' transaction. It also mentions a 'Limit for number of shares' at 5%. This structure—reporting the quantity and percentage of shares held by an individual or entity, especially when crossing a threshold or reporting a significant change—is characteristic of a Major Shareholding Notification. The filing type code corresponding to this is MRQ (Major Shareholding Notification). The document length is short (3007 chars), but the content is a direct report of the holding change, not an announcement of a report's publication.
2021-12-07 English
A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" dated December 6, 2021. It announces the presentation of study results (A BLINDED EVALUATION OF THE CONNECTION STUDY) at a conference (2021 Hot Topics in Neonatology®) and provides key findings regarding the drug candidate IBP-9414. It is not a full annual report (10-K), an interim report (IR), or a formal regulatory filing like a DEF 14A or DVA. It is an announcement of clinical/scientific findings, which most closely aligns with an Earnings Release (ER) if it were tied to quarterly results, or more generally, a Regulatory Filing (RNS) as it is a press release announcing scientific data. However, since it is a press release announcing scientific/clinical data rather than financial earnings highlights, and it provides a link to the scientific poster, it functions as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing study results that doesn't fit the specific financial/governance categories, although 'ER' is sometimes used broadly for results announcements. Since this focuses purely on clinical study validation and presentation, RNS is the best fit as a general regulatory/corporate announcement.
2021-12-06 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.